FDA approves cell-based gene therapy to treat adults with relapsed or refractory large-B-cell lymphoma
Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with
Read more